Evidence map›Paper›PMID 38587392›Full record

ArticleAntimicrobial agents and chemotherapy2024

Influenza C virus susceptibility to antivirals with different mechanisms of action.

Anton Chesnokov, Andrei A Ivashchenko, Yoko Matsuzaki, Emi Takashita, Vasiliy P Mishin, Alexandre V Ivachtchenko, Larisa V Gubareva

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Anton ChesnokovInfluenza Division, NCIRD, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.ORCID 0000-0001-5240-1883
Andrei A IvashchenkoChemDiv, San Diego, California, USA.
Yoko MatsuzakiDepartment of Infectious Diseases, Yamagata University Faculty of Medicine, Yamagata, Japan.
Emi TakashitaResearch Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Tokyo, Japan.
Vasiliy P MishinInfluenza Division, NCIRD, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
Alexandre V IvachtchenkoChemDiv, San Diego, California, USA.
Larisa V GubarevaInfluenza Division, NCIRD, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
Centers for Disease Control and Prevention · USChemDiv (United States) · USNational Institute of Infectious Diseases · JPYamagata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiviral susceptibility of influenza viruses was assessed using a high-content imaging-based neutralization test. Cap-dependent endonuclease inhibitors, baloxavir and AV5116, were superior to AV5115 against type A viruses, and AV5116 was most effective against PA mutants tested. However, these three inhibitors displayed comparable activity (EC

Indexed as

Antiviral AgentsDibenzothiepinsTriazinesAnimalsAntibodies, MonoclonalCyclopropanesDogsGammainfluenzavirusHumansInfluenza A virusMadin Darby Canine Kidney CellsMorpholinesNeutralization TestsPyridinesPyridonesAntibodies, MonoclonalAntiviral AgentsbaloxavirCyclopropanesDibenzothiepinsMorpholinesPyridinesPyridonesTriazinesbaloxavircap-dependent endonuclease inhibitorsdrug susceptibilitylectinpolymerase

Identifiers

PMID38587392
PMCPMC11064526
OpenAlexW4394578833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.